Edwards Lifesciences Corporation
—- Market cap
- $49.07B
- Debt
- —
- Cash
- −$2.94B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EW stock price vs BRKR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BRKR's multiple
Needs BRKR P/E.
Implied fair value · at EW's multiple
Needs Annual EPS is negative.
Snapshot Sep 11, 2026, 10:39 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRUKER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
EW vs ABT
JOHNSON & JOHNSON
EW vs JNJ
Medtronic plc
EW vs MDT
BOSTON SCIENTIFIC CORP
EW vs BSX
BAXTER INTERNATIONAL INC
EW vs BAX
DENTSPLY SIRONA Inc.
EW vs XRAY
THERMO FISHER SCIENTIFIC INC.
EW vs TMO
DANAHER CORP /DE/
EW vs DHR
AGILENT TECHNOLOGIES, INC.
EW vs A
WATERS CORP /DE/
EW vs WAT
BIO-RAD LABORATORIES, INC.
EW vs BIO
BIO-TECHNE Corp
EW vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EW can sustain its superior growth, margins, and returns at a premium multiple, then hold or accumulate on weakness because the fundamentals clearly outrun BRKR even if the relative valuation screen looks stretched.
EW trades at a P/S of 8.5x versus BRKR at 2.3x, which is the main driver of the modeled discount to BRKR-implied value. That said, EW's current price of $89.32 is still near the top of its historical band and well above BRKR-implied and DCF ranges, so the market is paying for quality rather than just growth.
Supporting Metrics